BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...

By Yahoo! Finance | Nov 5, 2024 at 02:06 AM EST

Helen Thackray aims to demonstrate the effectiveness of Netherton syndrome treatment by focusing on skin penetration, target binding, and functional cure potential. Charlie Gayer expects continued ORLADEYO revenue growth despite Q4 slowdown from patient approval challenges and holiday timing.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.